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Abstract
Background Recent guidelines suggested a wider use of long-acting injectable antipsychotics (LAI) than previously, but 
naturalistic data on the consequences of LAI use in terms of discontinuation rates and associated factors are still sparse, 
making it hard for clinicians to be informed on plausible treatment courses.
Objective Our objective was to assess, under real-world clinical circumstances, LAI discontinuation rates over a period of 
12 months after a first prescription, reasons for discontinuation, and associated factors.
Methods The STAR Network ‘Depot Study’ was a naturalistic, multicentre, observational prospective study that enrolled 
subjects initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centres 
were assessed at baseline and at 6 and 12 months of follow-up. Psychopathology, drug attitude and treatment adherence were 
measured using the Brief Psychiatric Rating Scale, the Drug Attitude Inventory and the Kemp scale, respectively.
Results The study followed 394 participants for 12 months. The overall discontinuation rate at 12 months was 39.3% (95% 
confidence interval [CI] 34.4–44.3), with paliperidone LAI being the least discontinued LAI (33.9%; 95% CI 25.3–43.5) and 
olanzapine LAI the most discontinued (62.5%; 95% CI 35.4–84.8). The most frequent reason for discontinuation was onset 
of adverse events (32.9%; 95% CI 25.6–40.9) followed by participant refusal of the medication (20.6%; 95% CI 14.6–27.9). 
Medication adherence at baseline was negatively associated with discontinuation risk (hazard ratio [HR] 0.853; 95% CI 
0.742–0.981; p = 0.026), whereas being prescribed olanzapine LAI was associated with increased discontinuation risk 
compared with being prescribed paliperidone LAI (HR 2.156; 95% CI 1.003–4.634; p = 0.049).
Conclusions Clinicians should be aware that LAI discontinuation is a frequent occurrence. LAI choice should be carefully 
discussed with the patient, taking into account individual characteristics and possible obstacles related to the practicalities 
of each formulation.
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formulations of antipsychotics were developed in the early 
1960s to enhance treatment adherence, although for many 
years they have been generally perceived as a last resort 
for patients with severe schizophrenia and even criticised as 
a coercive tool [2]. However, the evidence accompanying 
the introduction of second-generation antipsychotic (SGA) 
LAIs has led experts and guidelines to reconsider the role 
of these formulations, advocating for earlier and wider use, 
including in patients at their first episode of psychosis and 
in those with diagnoses other than schizophrenia [3–8]. In 
recent times, LAIs have been largely destigmatized by clini-
cians, and several strategies to address barriers towards LAI 
employment have been proposed [9].
1 Introduction
Antipsychotic discontinuation and lack of adherence repre-
sent major risk factors for relapse in people with both affec-
tive and non-affective psychoses and are key challenges for 
frontline practitioners [1]. Long-acting injectable (LAI) 
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Key Points 
The STAR Network ‘Depot Study’ prospectively fol-
lowed 394 subjects initiating treatment with long-acting 
injections (LAIs) of antipsychotics under naturalistic 
conditions for 12 months.
LAI discontinuation was frequent in everyday clinical 
practice in Italy, occurring in almost 40% of the entire 
sample; side effects, participant refusal to continue LAIs 
and LAIs no longer being required were the most fre-
quently reported reasons for discontinuation.
Paliperidone LAI and aripiprazole LAI were the least 
discontinued medications (33.9 and 35.4%, respectively), 
whereas more than half of participants initiating risperi-
done LAI and olanzapine LAI discontinued during the 
12 months of follow-up (51.4 and 62.5%, respectively).
In multivariate analysis, being prescribed olanzapine 
LAI and poor medication adherence at baseline were 
significantly associated with higher discontinuation risk.
antipsychotics, whereas studies comparing different LAIs 
with each other either did not include the most recently mar-
keted SGA LAIs or did not explore sociodemographic and 
clinical characteristics possibly associated with LAI adher-
ence [14–16].
Against this background, the present study was conducted 
to assess the proportion of subjects discontinuing LAI medi-
cations over a period of 12 months after an LAI prescription 
to ascertain whether different LAI medications are associ-
ated with different discontinuation rates, reasons for discon-
tinuation and to explore factors possibly associated with the 
risk of discontinuation.
2  Methods
2.1  Study Design and Inclusion Criteria
This study was developed following the STROBE (STrength-
ening the Reporting of OBservational studies in Epidemiol-
ogy) statement [17]. The full description of the methods of 
the STAR Network Depot Study and cross-sectional data 
analyses are reported elsewhere [18, 19]. Briefly, the STAR 
Network Depot Study was an observational, longitudinal 
multicentre study involving subjects initiating treatment with 
any LAI, consecutively recruited over a period of 12 months 
and assessed at 6 and 12 months of follow-up. Subjects 
were included if they were (1) adults (aged ≥ 18 years), (2) 
willing to sign the informed consent, (3) initiating an LAI 
medication and (4) not receiving any other LAI during the 
previous 3 months. Given the pragmatic nature of the study, 
participants with any psychiatric diagnosis and any concom-
itant pharmacological treatment were included. Similarly, 
participants from any setting, including hospital psychiatric 
wards, community day centres and residential facilities, were 
included. Recruiting centres were part of the STAR Network 
(Servizi Territoriali Associati per la Ricerca—Community 
Services Associated for Research), an Italian research net-
work aiming to gather original data from real-world clinical 
practice and provide new pragmatic insights for clinicians.
The study protocol was approved by the local ethics com-
mittees of recruiting centres and was made publicly available 
at the Open Science Framework online repository (https:// 
osf. io/ wt8kx/). Participants provided written consent for the 
collection and analysis of their data. The STAR Network 
Depot Study was conducted independently of industry fund-
ing or support.
2.2  Measures
A standard form was used to collect sociodemographic (age, 
sex, education, marital status), clinical (diagnosis, number 
and days of hospitalizations during the last year, alcohol/
However, whether different LAI medications are associ-
ated with different discontinuation rates and, more generally, 
with different patient outcomes, including attitudes towards 
medications, functioning and quality of life, remains uncer-
tain [10]. Randomized controlled trials (RCTs) are usually 
regarded as the gold standard for evaluating the efficacy of 
medications, but in the case of LAIs they suffer from major 
limitations. A first issue is selection bias, as participants 
with low treatment adherence (who are likely to benefit 
the most from LAIs) might not be suitable for enrolment 
in RCTs [11]. Additionally, as study participation requires 
willingness to participate and adherence to complex proce-
dures (e.g. double-dummy techniques), by definition, trial 
participants cannot be representative of difficult-to-treat 
patients who are generally reluctant to engage with mental 
health services [12]. Another concern is that RCTs require 
an artificial ecology that inevitably favours treatment adher-
ence, and that is quite different from the real world of ordi-
nary clinical practice [13].
Theoretically, observational studies, by following unse-
lected cohorts of everyday patients over long periods of 
follow-up under everyday circumstances, may offer a bet-
ter perspective to describe discontinuation rates associated 
with different LAI antipsychotics. Surprisingly, relatively 
few such studies have been conducted, and heterogeneous 
methodological approaches have been used, making it dif-
ficult to draw any clear conclusions. Some observational 
studies focused on one LAI antipsychotic only, comparing it 
with the corresponding oral medication or a mixture of oral 
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substance-related disorders, metabolic comorbidities) and 
pharmacological information (current and previous treat-
ments, LAI prescribed, side effects). Clinical interviews, 
health records and chart reviews were used to collect par-
ticipants’ baseline data. A follow-up form was used to col-
lect treatment data, including date and reasons (through 
checklist) for LAI discontinuation. In addition, the following 
rating scales were used: (1) The clinician-rated Brief Psychi-
atric Rating Scale (BPRS) [20], validated in the Italian lan-
guage [21], assessed the overall level of psychiatric symp-
toms, with scores ranging from 31 to 40 indicating mild 
symptoms, from 41 to 52 moderate symptoms, and above 
52 severe symptoms [22]; (2) the self-administered Drug 
Attitude Inventory 10 items (DAI-10) [23], validated in the 
Italian language [24], measured the subject’s attitude toward 
medications, with scores ranging between − 10 and 10 and 
higher scores indicating a better overall attitude toward med-
ications; (3) the clinician-rated Kemp’s 7-point scale [25], 
compiled by the clinician, assessed overall adherence to 
treatments, with scores ranging from 1 to 7 and higher scores 
indicating equally higher levels of adherence and scores of 
≥5 indicating an overall good acceptance of medications. 
These rating scales were administered at baseline and after 
6 and 12 months of follow-up.
2.3  Data Management and Statistical Analysis
Baseline and follow-up data were periodically forwarded 
from each recruiting centre to the coordinating centre (Uni-
versity of Verona), where they were entered into a computer 
database. Data correctness and consistency were ensured 
with the use of a double-entry technique and by applying a 
set of electronic and manual edit checks. Participants’ data 
were recorded anonymously. A unique number for each par-
ticipant was used both in the recruitment and the follow-up 
forms, and confidentiality was guaranteed throughout the 
entire course of the study, in accordance with the Declara-
tion of Helsinki [26].
Continuous variables were expressed as means and 
standard deviations, whereas categorical variables were 
expressed as absolute numbers and percentages. Statistical 
significance was assessed using the Mann–Whitney U test 
for continuous variables, and through the chi-squared test or 
Fisher’s exact test as appropriate for categorical variables. 
A Kaplan–Meier survival curve was plotted to describe the 
proportion of participants discontinuing first-generation 
antipsychotics (FGAs), considered as a group, and each 
SGA LAI over the time. To identify factors associated with 
LAI discontinuation, a multiple regression, including a ran-
dom effect per centre, was performed. As the variance of 
this random effect was not significantly different from 0, we 
then performed non-parametric Cox regressions without a 
random effect. Statistical analyses were performed with the 
software Stata version 15.1 [27].
3  Results
3.1  Participant Characteristics
The study included 461 subjects initiating treatment with 
an LAI, recruited in 35 Italian centres. As three recruiting 
centres contributed only to the cross-sectional phase of the 
study, 31 participants were not included in the longitudinal 
assessment, and 36 additional participants refused to give 
consent for the follow-up assessment. Overall, 394 partici-
pants recruited in 32 centres provided data for the survival 
analysis. Figure 1 presents the number of participants and 
their distribution among the diagnostic categories for each 
LAI. The majority of the sample received SGA LAIs (67%). 
Paliperidone LAI (once monthly) was the most frequently 
prescribed medication, followed by aripiprazole LAI (ari-
piprazole monohydrate), haloperidol LAI, risperidone LAI, 
fluphenazine LAI, olanzapine LAI, zuclopenthixol LAI 
and perphenazine LAI. Schizophrenia was the most com-
mon diagnosis, accounting for more than 50% of study 
participants.
During the 1-year follow-up, a total of 155 participants 
discontinued treatment with the LAI prescribed at baseline, 
yielding a discontinuation rate of 39.3% (95% confidence 
interval [CI] 34.5–44.4). Table 1 presents the main baseline 
sociodemographic and clinical characteristics of participants 
continuing and discontinuing treatment with LAI antipsy-
chotics. Compared with those who did not discontinue, 
participants discontinuing treatment during follow-up had 
poorer attitudes towards medications (as measured by the 
DAI-10 scale) and were considered less adherent (as meas-
ured by the Kemp scale). Discontinuers were significantly 
older (by an average of approximately 2 years), although 
illness duration was slightly shorter than in continuers. Diag-
nostic categories were balanced between continuers and 
discontinuers, and no significant differences were found in 
terms of BPRS scores, although more participants discon-
tinuing treatment had been involuntarily hospitalized prior 
to the study1.
3.2  Survival Probability for Long‑Acting Injectable 
(LAI) Antipsychotics
The Kaplan–Meier survival estimate showed that paliperi-
done LAI was the least discontinued antipsychotic (33.9%; 
95% CI 25.3–43.5), followed by aripiprazole LAI (35.4%; 
1 Italian law does not provide for compulsory community treatment.
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95% CI 26.0–45.3) and by the group of FGA LAIs (40.8%; 
95% CI 32.2–49.7). Risperidone LAI (51.4%; 95% CI 
34.4–68.1) and olanzapine LAI (62.5%; 95% CI 35.4–84.8) 
were the only antipsychotics with a discontinuation rate 
greater than 50% and had a significantly higher hazard of 
discontinuation than paliperidone LAI, the best-performing 
agent (Fig. 2). Table S1 in the electronic supplementary 
material (ESM) shows the discontinuation rates for each 
LAI.
3.3  Reasons for LAI Discontinuation
The most frequently reported reason for LAI discontinua-
tion was the occurrence of adverse events (32.9%; 95% CI 
25.6–40.9), followed by participant refusal of continuing 
treatment (20.6%; 95% CI 14.6–27.9) and the clinician con-
sidering the LAI to be no longer required (20.0%; 95% CI 
14.0–27.2). LAI inefficacy was the least frequently reported 
reason for discontinuation (17.4%; 95% CI 11.8–24.3) 
(Table 2). Adverse events that led to LAI discontinuation, 
and discontinuation reasons for each LAI, are reported in 
Tables S2 and S3 in the ESM, respectively.
3.4  Factors Associated with LAI Discontinuation
After adjustment for a number of confounders, non-par-
ametric Cox regression analysis revealed that receiving 
olanzapine LAI, as compared with paliperidone LAI, the 
best-performing agent, significantly increased the risk of 
discontinuation. Lower adherence at baseline, as measured 
by the Kemp scale, was additionally associated with a higher 
risk of discontinuation (Table 3).
4  Discussion
This study described the longitudinal time course of LAI 
discontinuation in an unselected group of subjects enrolled 
in the context of everyday clinical practice by an Italian 
network of mental health services. Study findings showed 
that LAIs are commonly prescribed to people with a broad 
spectrum of diagnoses, including not only schizophre-
nia but also bipolar disorder, personality disorders and 
organic mental disorders, although a registered therapeutic 
indication by the Italian Medicines Agency exists only 
for schizophrenia. Most of the participants received SGA 
LAIs, with paliperidone and aripiprazole being the most 
frequent choices, followed by the FGA LAI haloperidol. 
Notably, participants were recruited in a variety of settings 
and types of mental health services, including outpatient, 
inpatient, academic and non-academic facilities. This 
choice was made to resemble real-world practice insofar 
as possible.
Fig. 1  Distribution of participants receiving a first long-acting inject-
able antipsychotic prescription by diagnostic category. Error bars rep-
resent 95% confidence intervals. FGA first-generation antipsychotic, 
LAI long-acting injectable antipsychotic. *Haloperidol LAI n  =  85, 
fluphenazine LAI n = 27, zuclopenthixol LAI n = 16, perphenazine 
LAI n = 2
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Despite being one of the most relevant strengths of this 
study, it also complicates the comparison with available lit-
erature, as differences in terms of study methods, local clini-
cal practice and socio-economic context may influence point 
estimates of discontinuation rates and associated factors.
The finding of an overall discontinuation rate of around 
40% over 12 months of follow-up, with olanzapine LAI and 
risperidone LAI showing the highest discontinuation rates 
(62.5 and 51.4%, respectively), takes place among the vari-
able retention rates previously reported. Using administra-
tive prescription databases in the Netherlands and Belgium, 
Decuypere et al. [28] documented discontinuation rates 
above 50% after 12 months of follow-up for paliperidone 
once monthly, risperidone LAI, olanzapine LAI and halop-
eridol LAI. Higher treatment continuation of paliperidone 
once monthly compared with risperidone LAI and haloperi-
dol decanoate were observed in both countries, together with 
a significantly higher treatment continuation of paliperidone 
once monthly compared with olanzapine LAI in the Neth-
erlands. Among British cohorts of patients beginning LAI 
treatment, discontinuation rates at 1 year were 35–40% for 
paliperidone once monthly [29–31] and 68–55% for risp-
eridone LAI [32, 33]. Iwata et al. [15] found discontinu-
ation rates for aripiprazole of around 40% among patients 
with schizophrenia in Japan at 12 months of follow-up [15], 
whereas, in Canada, treatment retention at 18 months was 
77% for a group of 70 patients with schizophrenia initiated 
with risperidone LAI [34]. On the other hand, in the USA, 
Pilon et al. [35] found notably higher discontinuation rates, 
with more than 60% of patients with schizophrenia using ari-
piprazole LAI, paliperidone once monthly and risperidone 
LAI discontinuing treatment after 12 months. Another study 
conducted in the USA reported that around 75% of patients 
with schizophrenia and bipolar disorder who initiated 
Table 1  Baseline sociodemographic and clinical characteristics of participants continuing and discontinuing long-acting antipsychotics over the 
12 months after first prescription
Data are presented as mean ± standard deviation or n (%) unless otherwise indicated. Bold formatting represents statistically significant results
BPRS Brief Psychiatric Rating Scale, DAI Drug Attitude Inventory, DDD defined daily dose, LAIs long-acting injectables, n number of partici-
pants, PDD prescribed daily dose
a Includes dementia, mental organic disorder, mental retardation and drug-induced psychosis
Characteristic Discontinuers p-Value
No (n = 239) Yes (n = 155)
Age 41.6 ± 13.1 43.8 ± 13.2 0.001
Women 86 (36.0) 67 (43.2) 0.150
Italian nationality 214 (90.3) 135 (87.1) 0.322
At least moderate housing self-sufficiency 89 (37.2) 78 (50.3) 0.010
Married 35 (14.6) 20 (12.9) 0.626
High school or higher education 113 (47.9) 78 (51.0) 0.550
Employed 51 (21.3) 33 (21.3) 0.991
Diagnosis
 Schizophrenia 126 (52.7) 82 (52.9) 0.152
 Schizoaffective disorder 38 (15.9) 32 (20.6)
 Bipolar disorder 52 (21.8) 22 (14.2)
 Personality disorders 11 (4.6) 14 (9.0)
 Organic mental  disordersa 8 (3.3) 3 (1.9)
 Obsessive-compulsive disorder 2 (0.8) 2 (1.3)
Years of illness 12.6 ± 9.8 10.9 ± 10.3 0.014
Alcohol use 39 (16.3) 23 (14.8) 0.694
Any substance use 50 (20.9) 32 (20.6) 0.948
At least one medical comorbidity 75 (31.4) 44 (28.4) 0.527
At least one hospitalization in the last year 138 (57.7) 102 (65.8) 0.109
At least one compulsory hospitalization 40 (16.8) 39 (25.2) 0.043
Psychotropic drug dose, PDD/DDD 1.2 ± 2.0 0.9 ± 0.8 0.319
LAIs in the past 75 (31.4) 45 (29.0) 0.621
BPRS 48.7 ± 14.0 49.7 ± 14.4 0.436
DAI-10 2.5 ± 5.2 1.2 ± 5.3 0.021
Kemp’s 7-point scale 5.0 ± 1.5 4.4 ± 1.4 < 0.001
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aripiprazole LAI discontinued treatment after 1 year [14]. 
In Austria, Rittmannsberger et al. [36], who analysed a total 
of 194 treatment episodes with new start of LAIs, found 
that almost one-half of patients dropped out after 6 months 
of follow-up.
The finding of higher discontinuation rates for olanzap-
ine LAI and risperidone LAI compared with the best-per-
forming agent, paliperidone LAI, reinforces the notion that 
very pragmatic reasons may influence treatment adherence 
in clinical practice. For olanzapine LAI, the risk of post-
injection delirium syndrome and the mandatory 3-h post-
administration monitoring period in appropriate facilities are 
important barriers to long-term use, and similar considera-
tions might apply to LAI medications requiring bimonthly 
administration, such as risperidone LAI.
Occurrence of adverse events was reported as the most 
frequent reason for LAI discontinuation, whereas lack of 
efficacy was seldom reported. These results are not in line 
with those from several similar pharmacoepidemiological 
studies, in which lack of effectiveness played a substantial 
role as reason for discontinuation. For instance, in a catch-
ment area of south London, 52% of a sample of patients on 
paliperidone palmitate discontinued treatment for lack of 
effectiveness, whereas adverse events accounted for 14.5% 
of discontinuations [31]. In the same catchment area, for 
risperidone LAI, Taylor et al. [37] reported lack of efficacy 
and adverse events in 38 and 29% of those who discontinued, 
respectively. A possible explanation for the high proportion 
of discontinuations related to adverse events observed in the 
present study may be that many participants initiated LAI 
treatment without previous treatment with the oral formula-
tion of the same antipsychotic. This might have increased the 
proportion of discontinuers due to adverse effects. However, 
the Cox regression did not support this explanation, as it did 
not find any association between absence of previous treat-
ment with oral formulation and discontinuation risk. This 
suggests that further factors may have influenced tolerability 
over time (e.g. dose adjustments) and that clinicians should 
be continuously alerted to the occurrence of clinically rel-
evant side effects, even after several months of treatment.
Interestingly, around 20% of LAI discontinuations was 
motivated by the LAI formulation being no longer required, 
which may reflect that individual needs and preferences may 
vary over time, for instance due to progressive improve-
ment of the underlying psychopathology, increased illness 
awareness and/or improved attitude towards medications, 
but also environmental changes, such as psycho-social sup-
port or admission to residential programmes with super-
vised drug administration. Therefore, in these cases, dis-
continuation should not be considered a negative outcome, 
highlighting the relevance of periodically reconsidering the 
Fig. 2  Kaplan–Meier survival 
estimate of the probability of 
continuing antipsychotic long-
acting injectable antipsychotics 
during the 12 months after ini-
tial prescription. *Statistically 
significant difference between 
risperidone LAI and paliperi-
done LAI (HR 2.014; 95% 
CI 1.152–3.522; p = 0.014). 
**Statistically significant dif-
ference between olanzapine 
LAI and paliperidone LAI (HR 
2.363; 95% CI 1.170–4.774; 
p = 0.017). CI confidence 
interval, FGA first-generation 
antipsychotic, HR hazard ratio, 
LAI long-acting injectable 
antipsychotic
Table 2  Reasons for discontinuing long-acting antipsychotics over 
the 12 months after first prescription
This information was not available for 14 participants
CI confidence interval, LAI long-acting injectable antipsychotic, n 
number of participants
Reason n % (95% CI)
Adverse events 51 32.9 (25.6–40.9)
Participant’s refusal 32 20.6 (14.6–27.9)
LAIs no longer required 31 20.0 (14.0–27.2)
Inefficacy 27 17.4 (11.8–24.3)
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appropriateness of current therapies, without considering 
LAIs only as a last resort approach with no return. Interest-
ingly, other studies reported lower rates of discontinuation 
motivated by the LAI formulation being no longer required. 
For instance, Deslandes et al. [29] reported that only 13% 
of a sample of patients receiving risperidone LAI discontin-
ued treatment based on patient choice or request; similarly, 
Attard et al. [31] found that only 17% of a sample of patients 
receiving paliperidone palmitate discontinued treatment 
based on patient preferences and choices. In the context of 
the present study, it is possible that cultural factors related 
to generic negative views that LAI formulations often have 
among doctors and patients motivated higher proportions 
of discontinuations based on reasons not related to efficacy 
or tolerability, but, rather, related to patients’ views and 
requests.
Although participants’ refusal to continue the LAI medi-
cation accounted for only about one-fifth of discontinua-
tions, the present study showed that the level of adherence 
at baseline was associated with discontinuation risk over the 
subsequent 12 months of follow-up. Of note, no other soci-
odemographic or clinical characteristics emerged as relevant 
factors. In particular, no diagnosis was associated with a 
higher likelihood of LAI discontinuation. Within this cohort, 
Table 3  Factors associated with the hazard of discontinuing long-acting antipsychotics over the 12 months after first prescription: multiple Cox 
regression analysis
Bold formatting represents statistically significant results
BPRS Brief Psychiatric Rating Scale, CI confidence interval, DAI Drug Attitude Inventory, DDD defined daily dose, FGA first-generation antip-
sychotic, HR hazard ratio, LAIs long-acting injectables, n number of participants, PDD prescribed daily dose, ref. reference
Variables Multiple regression (n = 390)
HR 95% CI p-Value
Age (years) 1.009 0.991–1.026 0.326
Female sex 0.965 0.652–1.429 0.858
Not Italian 1.024 0.576–1.823 0.937
At least moderate housing self-sufficiency 1.444 0.948–2.200 0.087
High school or higher education 1.113 0.785–1.578 0.549
Employed 1.136 0.745–1.732 0.554
PDD/DDD 0.946 0.850–1.052 0.305
Alcohol use 0.706 0.406–1.225 0.215
Substance use 1.305 0.791–2.152 0.298
Number of medical comorbidities 0.871 0.571–1.327 0.520
BPRS score 0.998 0.984–1.011 0.766
DAI-10 score 0.983 0.949–1.019 0.358
Kemp score 0.849 0.739–0.976 0.021
Number of LAIs in the past 0.846 0.657–1.089 0.194
Cumulative days of hospitalizations in the last year 0.998 0.988–1.008 0.691
Compulsory admissions in the last year 0.888 0.567–1.391 0.603
Number of previous antipsychotic drugs 0.809 0.384–1.705 0.577
Prior clozapine use 1.680 0.825–3.419 0.152
Inpatient when starting LAI 1.050 0.726–1.520 0.794
Oral trial before LAI administration 0.803 0.519–1.244 0.327
LAI
 Paliperidone LAI 1 (ref. category)
 FGA LAIs 0.981 0.606–1.588 0.937
 Risperidone LAI 1.581 0.855–2.921 0.144
 Aripiprazole LAI 1.220 0.731–2.037 0.446
 Olanzapine LAI 2.367 1.058–5.295 0.036
Diagnosis
 Schizophrenia and related psychosis 1 (ref. category)
 Bipolar disorder 0.674 0.409–1.111 0.122
 Other diagnoses 1.295 0.751–2.234 0.352
Prescriber’s age 0.998 0.982–1.015 0.813
 F. Bertolini et al.
we could not confirm some previously reported predictors 
of discontinuation, such as inpatient status at LAI initiation 
[31, 38], having had an adequate oral trial [30] or history 
of treatment resistance (in the form of number of previous 
antipsychotics trials or prior clozapine use) [39]. The studies 
that found these variables as predictors did consider cohorts 
initiated on paliperidone once monthly or risperidone LAI 
and considered specific local areas. It is possible that not all 
LAIs share these predictors or that our multicentre cohort 
was underpowered to detect these associations. However, 
other single-centre studies (where overall heterogeneity can 
be expected to be considerably lower than in our study) were 
also unable to find discontinuation predictors [29, 30].
Limitations of the present study are those related to the 
naturalistic approach employed. We acknowledge that, 
although discontinuation rate may be considered a highly 
pragmatic outcome measure, especially in difficult-to-treat 
patient populations such as those with psychotic disorders, 
lack of an experimental design prevents us from drawing 
conclusions related to the comparative efficacy of LAIs. 
However, the present study can inform on the practical con-
sequences of initiating different LAI medications in real-
world settings. A second limitation is that, for some LAIs, 
particularly olanzapine LAI and risperidone LAI, the num-
ber of participants was relatively low, limiting the precision 
of our estimates. Moreover, a larger sample size would have 
enabled analysis of the reasons leading to individual LAI 
discontinuations. The regulatory requirement for written 
informed consent for data collection might have led to non-
inclusion of some patients (e.g., those affected by severe 
paranoid symptoms). However, the baseline clinical charac-
teristics do not suggest a lack of representation of subjects 
with severe symptoms. An additional shortcoming is that, at 
the time the study was conducted, paliperidone 3-monthly 
LAI was not available in Italy.
5  Conclusions
Clinicians should be aware that LAI discontinuation is a fre-
quent occurrence in clinical practice and that regular assess-
ment of adherence levels before and during LAI treatment 
might be helpful to predict and monitor this risk. The choice 
of the LAI should be carefully discussed with the patient, 
taking into account not only the efficacy and tolerability 
profile in light of the patient’s individual characteristics but 
also possible obstacles related to the practicality of the for-
mulation. In particular, clinicians should explicitly ask about 
patient and caregiver views on the interval between admin-
istrations, the need for oral supplementation, the need for 
clinical observation after injection, any fear of needles and 
the expected tolerance to local site pain. Our results suggest 
that individuals initiated on olanzapine LAI and risperidone 
LAI may experience higher discontinuation rates than those 
receiving other LAI medications.
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